ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $41,000 | -32.8% | 870 | +2.1% | 0.00% | – |
| Q1 2022 | $61,000 | +335.7% | 852 | +343.8% | 0.00% | – |
| Q4 2021 | $14,000 | +40.0% | 192 | +5.5% | 0.00% | – |
| Q3 2021 | $10,000 | +25.0% | 182 | -0.5% | 0.00% | – |
| Q2 2021 | $8,000 | -27.3% | 183 | -20.8% | 0.00% | – |
| Q1 2021 | $11,000 | +450.0% | 231 | +477.5% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 40 | +100.0% | 0.00% | – |
| Q3 2020 | $1,000 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |